The present disclosure provides a system of gender specific pharmaceuticals. The system includes a first package of a pharmaceutical for use by a male and a second package of a pharmaceutical for use by a female. The first package includes at least one male dosage having a first dosage amount, an insert positioned in the first package, the insert including a recommended male dosage and a recommended female dosage that is different than the male dosage, and a male label coupled to the first package, the label including a male gender specifier. The female package includes at least one female dosage having a second dosage amount that is smaller than the first dosage amount, an insert positioned in the first package, the insert including a recommended male dosage and a recommended female dosage that is different than the male dosage, and a female label coupled to the second package, the female label including a female gender specifier, wherein the female gender specifier is different than the male gender specifier.

The disclosure includes a method for providing prosthetic implants for a total knee replacement procedure. This method includes receiving data representative of a knee joint of a patient and determining anatomical parameters from the received data. The method also includes creating a graphical model of the knee joint based on the determined anatomical parameters, and providing a femoral component of a knee joint implant based on at least one of the determined anatomical parameters and the graphical femoral portion. This method also includes providing at least one cutting instrument configured to facilitate removing a portion of the femur of the patient based on at least one of determined anatomical parameters and the graphical model.

Implantable in vivo sensors used to monitor physical, chemical or electrical parameters within a body. The in vivo sensors are integral with an implantable medical device and are responsive to externally or internally applied energy. Upon application of energy, the sensors undergo a phase change in at least part of the material of the device which is then detected external to the body by conventional techniques such as radiography, ultrasound imaging, magnetic resonance imaging, radio frequency imaging or the like. The in vivo sensors of the present invention may be employed to provide volumetric measurements, flow rate measurements, pressure measurements, electrical measurements, biochemical measurements, temperature, measurements, or measure the degree and type of deposits within the lumen of an endoluminal implant, such as a stent or other type of endoluminal conduit. The in vivo sensors may also be used therapeutically to modulate mechanical and/or physical properties of the endoluminal implant in response to the sensed or monitored parameter.

An expandable stent for implanting in a body lumen, such as a coronary artery, peripheral artery, or other body lumen. In one aspect, the stent includes a butterfly pattern to which connecting links are attached. In another aspect, the stent embodies a non-directional structure.

A system of prosthetic implants for a total knee replacement procedure is provided. The system includes a tibial component of a knee joint implant, a tibial insert configured to be positioned against the superior side of the platform of the tibial component, a first femoral component of a knee joint implant, and a second femoral component of a knee joint implant.

A felting set (1) for attaching an implant (10) to soft tissue (2). The set comprises a felting device (20) and the implant, wherein the implant comprises a patch comprising a non-woven material made of individual fibers (11), wherein the fibers have a length of 20 to 80 mm, wherein the patch comprises a drug (12). The felting device includes a needle (21) with at least one blade (22) and with at least one barb (23; 24) for delivering the fibers of the patch into the soft tissue.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

A system and method are provided for treating an aneurysm or other vessel disease or defect. The present disclosure includes an expandable device for placement in a vessel, where the mechanically expandable device includes a membrane. Also disclosed is a delivery device constructed and arranged to position the expandable device such that the exterior surface of the expandable device engages with the inner surface of the vessel and maintains a fluid pathway through said vessel.